Practise 25 questions on Biotechnology and Medical Technology.
0 / 25 correct · click an option to check it · +0 pts today
Q1. Yellapragada Subbarow’s team developed Hetrazan in 1946, to treat which disease?
Show answer and explanation
Answer: C
Hetrazan (diethylcarbamazine) became a key drug against filariasis, later central to WHO’s elephantiasis campaign.
Q2. How can resistance developed in one bacterial infection spread to an unrelated infection?
Show answer and explanation
Answer: A
Bacteria can transfer resistance genes to each other directly, so resistance from one setting can spread to unrelated infections.
Q3. With reference to the Genetically Modified mustard (GM mustard) developed in India, consider the following statements: 1. GM mustard has the genes of a soil bacterium that give the plant the property of pest-resistance to a wide variety of pests. 2. GM mustard has the genes that allow the plant cross-pollination and hybridization. 3. GM mustard has been developed jointly by the IARI and Punjab Agricultural University.
Show answer and explanation
Answer: B
GM mustard (DMH-11) uses barnase/barstar genes from a soil bacterium for hybridization, not pest resistance, and was developed by Delhi University, not IARI/Punjab Agricultural University.
Q4. Asima Chatterjee developed the anti-epileptic drug Ayush-56 from which plant?
Show answer and explanation
Answer: B
Ayush-56, an anti-epileptic drug still in use, was developed from the plant Marsilea minuta.
Q5. Beyond drug delivery, how does nanotechnology also support early disease diagnosis?
Show answer and explanation
Answer: A
Nanotechnology in health also extends to diagnostics, such as nanoparticle-based sensors that detect disease markers early.
Q6. With reference to the use of nanotechnology in the health sector, consider: 1. Targeted drug delivery is made possible by nanotechnology. 2. Nanotechnology can largely contribute to gene therapy. Which is/are correct?
Show answer and explanation
Answer: C
Both statements are correct. Nanotechnology enables targeted drug delivery and contributes significantly to gene therapy.
Q7. In gene therapy, what specific problem do nanoparticles help solve when delivering genetic material like DNA or RNA?
Show answer and explanation
Answer: A
Nanoparticles help protect and deliver fragile genetic material that would otherwise degrade before reaching its target cells, making gene therapy more feasible.
Q8. Consider the following statements: 1. Genetic medicines can use engineered viruses as carriers. 2. Genetic medicine typically replaces a patients entire DNA sequence. 3. Ex vivo gene therapy modifies cells outside the body before returning them to the patient. Which of the statements given above is/are correct?
Show answer and explanation
Answer: A
Statements 1 and 3 are correct. MedlinePlus says viruses modified so they can’t cause disease are used as vectors, so statement 1 holds. Bulcha and colleagues describe ex vivo therapy as taking out a patient’s cells, changing them with a vector and infusing them back. MedlinePlus describes the same steps, so statement 3 holds. MedlinePlus says genome editing alters genetic material at precise locations in the genome. So statement 2, about replacing a patient’s entire DNA sequence, is wrong.
Q9. Which standard laboratory technique amplifies specific DNA segments outside a living cell?
Show answer and explanation
Answer: A
PCR is a standard technique that replicates or amplifies specific DNA segments in vitro, outside a living cell.
Q10. Consider the following statements about the transcriptome. 1. It is the set of RNA transcripts produced in a specific cell or under specific circumstances. 2. Comparing transcriptomes can reveal genes expressed differently in response to different treatments. 3. It is the set of DNA changes caused by mutations. Which statements are correct?
Show answer and explanation
Answer: A
Nature defines the transcriptome as RNA transcripts produced by the genome under specific circumstances or in a specific cell. It says comparing transcriptomes can identify genes expressed differently in response to different treatments. So statements 1 and 2 are correct. NHGRI defines a mutation as a change in the DNA sequence, so statement 3 is wrong.
Q11. How do the small RNA fragments produced during RNAi actually silence a gene?
Show answer and explanation
Answer: A
Small interfering RNA fragments guide a protein complex to destroy any matching messenger RNA, silencing that specific gene.
Q12. ‘RNA interference (RNAi)’ technology has gained popularity in the last few years. Why? 1. It is used in developing gene silencing therapies. 2. It can be used in developing therapies for the treatment of cancer. 3. It can be used to develop hormone replacement therapies. 4. It can be used to produce crop plants that are resistant to viral pathogens.
Show answer and explanation
Answer: A
RNAi genuinely supports gene-silencing therapies, cancer treatment research, and virus-resistant crops — but not hormone replacement therapy.
Q13. What triggers the RNA interference process inside a cell?
Show answer and explanation
Answer: A
RNAi begins when double-stranded RNA enters a cell, triggering machinery that chops it into small interfering RNA fragments.
Q14. Which statement about the National Sickle Cell Anaemia Elimination Mission is correct?
Q15. The HbS variant that causes sickle cell disease arises from which change in beta-globin?
Q16. Assertion (A): The HbS gene has persisted in malaria-prone populations. Reason (R): Sickle cell trait gives partial protection against severe falciparum malaria. Which one is correct?
Q17. Consider the following statements. 1. Sickle cell trait (HbAS) means one HbS gene and one normal HbA gene. 2. If both parents are carriers, each child has a 25% chance of HbSS. 3. Carriers usually have severe symptoms like those of HbSS. Which of the statements given above is/are correct?
Q18. Which statement about gene expression is correct?
Show answer and explanation
Answer: D
NHGRI says gene expression can be thought of as an on/off switch for when and where RNA and proteins are made. It is also a volume control for how much is made. NHGRI says it changes substantially under different conditions and cell types.
Q19. Which gene-editing tool changes one DNA base without a double-strand break or a donor template?
Show answer and explanation
Answer: B
David Liu’s lab reported base editing in 2016. Cas9 is fused to an enzyme that converts one base to another, such as C to T. The indel rate was low.
Q20. BIRSA-101 was developed at CSIR-IGIB. Which company has signed a technology transfer agreement to scale it up for affordable manufacturing?
Show answer and explanation
Answer: D
CSIR-IGIB signed a technology transfer agreement with the Serum Institute of India. The goal is to make the therapy affordable and scalable, supporting the target of a Sickle Cell-Free India by 2047.
Q21. Which disease does the marker-bred chickpea variety Super Annigeri-1 resist?
Show answer and explanation
Answer: B
ICAR released Super Annigeri-1 in September 2019. It is a chickpea variety that resists Fusarium wilt. ICAR lists it among crop varieties developed through molecular breeding. The marker used was an SSR.
Q22. Which institute gives India ocean state forecasts and tsunami advice?
Show answer and explanation
Answer: B
INCOIS in Hyderabad gives ocean forecasts and tsunami advice. NIOT builds technology and NCPOR runs polar work.
Q23. In what month and year did the Human Genome Project finish?
Show answer and explanation
Answer: A
The project finished in April 2003, over two years ahead of schedule, at a cost of about $2.7 billion.
Q24. What did the Human Genome Project accomplish?
Show answer and explanation
Answer: A
The Human Genome Project mapped the complete set of human genes. This gave scientists a reference map. The reference map covers human DNA.
Q25. Which of the following statements with regard to GenomeIndia Project is/are correct? 1. It is a part of the Human Genome Project. 2. The project is funded by the Department of Biotechnology (DBT), Government of India. 3. Its primary aim is to build a catalogue of genetic diversity of the Indian population. Select the answer using the code given below :
Show answer and explanation
Answer: B
The answer is (b) by the sources; UPSC had not published its key when checked. DBT funds the project. Its official title speaks of cataloguing genetic variation in Indians. The Human Genome Project ran from 1990 to 2003, before GenomeIndia began.
Share your thoughts